New Announcement
NEW!Click here for a free, online course on various data extraction tools, with a focus on SRDR+.The course is offered through the Evidence Synthesis Academy.
SRDR+:
Moving systematic reviews forward.
SRDR+ is a free, powerful, easy to use tool for data extraction, management, and archival during systematic reviews.
Already have an account?
Get started now.

See how you can work with SRDR+

Stock Icon

Researchers

Use SRDR+ as a free platform for extracting, archiving, and sharing data during systematic reviews and accessing shared data related to systematic reviews.
Stock Icon

Guideline Developers

Use SRDR+ for accessing data related to systematic reviews when producing guidelines and recommendation statements for their constituencies.
Stock Icon

Educators & Librarians

Use SRDR+ for instructing students and trainees in the best practices related to research methodology and evaluation.
Stock Icon

Clinicians

Use SRDR+ for quick reference to study data that are relevant to clinical questions based on systematic reviews.
Stock Icon

Policymakers

Use SRDR+ for quick reference to study data that are relevant to policy questions or recommendations based on systematic reviews.

Leading professionals love SRDR+

Image of Matthias Perleth

Mathias Perleth, MPH

Board Treasurer, International Network of Agencies for Health Technology Assessment [INAHTA], Germany
“In my regard, SRDR is among the most relevant developments in recent years!”
Image of Christine Clifford

Christine Clifford, MHP

Project Director, Eunice Kennedy Shriver Center, University of Massachusetts Medical School, USA
“I like SRDR’s use of the Tabs and the separation by topic area of the Tabs; it allows for focus on sections of a paper at a time. SRDR is powerful and adaptable, provides a way to standardize diverse results, and provides structure.“
Image of Tianjing Li

Tianjing Li, MD, MHS, PhD

Director, Cochrane Eyes and Vision United States Satellite, Associate Professor, Johns Hopkins Bloomberg School of Public Health, USA
“SRDR is one of the few data systems designed specifically for producing and archiving systematic reviews with the intention to share the data with the public. It’s extremely flexible and it allows users to design their forms (and data items on the forms) in a way that best suit their needs and workflow.”
Image of James Scott Parrott

James Scott Parrott, PhD

Professor, Rutgers University School of Health Professions, USA
“The structure of SRDR lends itself well to teaching metacognitive processes associated with linking the discrete steps of the evidence analysis process. Another benefit is the flexibility of SRDR to handle diagnostic accuracy as well as etiology, treatment, and prognosis questions during systematic reviews.”

Create your systematic review project today

SRDR+ has a variety of features that make it the best place to conduct systematic reviews.
Stock Icon
Build electronic data extraction forms
Stock Icon
Extract and compare data
Stock Icon
Collaborate with your team
Stock Icon
Customize exports of your datasets

Access study data from published systematic reviews today.

Stock Icon
Browse topics with available study data.
Stock Icon
Download study data
Stock Icon
Use study data in your own systematic review.

Recently published projects

Published on July 30, 2020
Therapies for Clinically Localized Prostate Cancer [Entered Retrospectively]
67 Studies • 1 Key Questions • 1 Extraction Forms
Objectives: Structured Abstract Objective. To identify new information that updates findings from previous AHRQ and AUA funded reviews evaluating therapies for clinically localized prostate cancer (CLPC). Sources. Bibliographic databases (2013-January 2020); ClinicalTrials.gov; systematic reviews Methods. Controlled studies of CLPC (T1-T3a) treatments with duration ≥5 years for mortality and metastases and ≥1 year for quality of life and harms. Interventions included watchful waiting (WW), active surveillance or monitoring (AS, AM), androgen deprivation (AD), focal and whole gland therapies or combinations. We evaluated how patient and tumor characteristics modify treatment outcomes and how provider/hospital characteristics modify effectiveness of radical prostatectomy (RP) compared to other therapies. One investigator rated risk of bias (ROB), extracted data, and assessed certainty of evidence; a second checked accuracy. We analyzed English-language studies with low or medium ROB. We incorporated findings from RCTs identified in the 2014 AHRQ and 2016 AUA funded reviews if new RCTs provided information on the same intervention comparison. We derived thresholds defining “small”, “moderate” and “large” effect, summarize key findings from prior reviews and the impact of new research. Results. We identified 67 eligible references; 17 unique RCTs. Among clinically, rather than PSA detected CLPC, WW may increase overall and prostate-cancer mortality, and metastases versus RP at 20+ years. Urinary and erectile dysfunction were lower with WW versus RP. WW‘s effect on mortality may have varied by tumor risk and age but not by race, health status, comorbidities or PSA. AM probably results in little to no difference in overall or prostate-cancer mortality in PSA detected CLPC versus RP or EBR plus AD through 10 years regardless of tumor risk. Metastases were infrequent but slightly higher with AM. Harms were greater with RP than AM and mixed between EBR plus AD versus AM. 3D-Conformal EBR and AD plus low-dose-rate brachytherapy (BT) provided a small reduction in all-cause mortality versus 3D-CRT and AD but little to no difference on metastases. EBR plus AD versus EBR alone may have resulted in a small reduction in overall and prostate-cancer mortality and metastases in higher risk disease but may increase sexual harms. EBR plus initiating neoadjuvant AD versus EBR plus initiating concurrent AD may result in little to no difference in mortality at 12 years and genitourinary toxicity at 3 years. Conventionally fractionated EBR versus ultra-hypofractionated EBR may result in little to no difference in mortality and metastasis at 5 years and urinary and bowel toxicity at 2 years. Limited evidence suggested that AS results in fewer harms than photodynamic therapy and laparoscopic RP resulted in more harms than robotic-assisted RP. There was little to no information on long-term comparative effectiveness of other treatments. No studies evaluated WW or AS in screen detected CLPC or MRI for risk assessment or were conducted since effective pharmacologic therapies for advanced disease. No studies assessed provider or hospital factors of RP comparative effectiveness. Conclusions. RP reduces mortality versus WW in clinically detected CLPC but causes more harms. Effectiveness may be limited to younger men, those with intermediate risk disease and requires many years to occur. AM results in little to no mortality difference versus RP or EBR plus AD. EBR plus AD reduces mortality versus EBR alone in higher risk CLPC but may worsen sexual function. Adding low-dose-rate BT to 3D-Conformal EBR and AD may reduce mortality in higher risk CLPC. Little information exists on other treatments or the effects of patient, tumor and provider factors. Large, long-term RCTs in PSA-detected and MRI staged CLPC are needed.
READ MORE
Published on February 12, 2019
SRDR Project Indexing
171 Studies • 1 Key Questions • 1 Extraction Forms
Objectives: This is a Methods Research project that catalogs the various projects with publicly available data on the SRDR Webpage.
READ MORE
Published on July 05, 2020
The effect of IDH inhibitors in AML patients.
4 Studies • 2 Key Questions • 1 Extraction Forms
Objectives: 12% of patients with AML harbor mutation at Isocitrate dehydrogenase enzyme (IDH).Mutations at these enzymes result in high level of R2 hydroxyglutarate which competes with 2-alpha-hydroxygluterate resulted in DNA and histone hypermethylation. DNA and histone hypermethylation inhibits cell differentiation and promotes leukemic transformation. Ivosidenib and Enasidenib are IDH inhibitors that promotes cell differentiation and showed promising activity in phase1 and 2 trials in relapse/refractory AML patients and in elderly patients who are not candidate for traditional induction regimens. In this systematic review and meta-analysis, we intend to integrate the results of phase1 and 2 trials that looked at the efficacy and the side effects of IDH inhibitor. Therefore,we will have a clearer picture regarding the efficacy and side effect of these medications.
READ MORE

Join thousands of professionals

TRY SRDR+ NOW